Reunion Neuroscience Reports $13.1M Take-Private Transaction With MPM BioImpact
Portfolio Pulse from Benzinga Newsdesk
Reunion Neuroscience announces a $13.1M take-private transaction with MPM BioImpact. Shareholders will receive $1.12 per share in cash, a 43.1% premium to the 30-day volume weighted average price. Reunion also presented positive Phase 1 results at the American Society of Clinical Psychopharmacology Annual Meeting, enabling Phase 2 advancement in 2H 2023.
June 01, 2023 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reunion Neuroscience's take-private transaction with MPM BioImpact values the company at $13.1M, offering shareholders a 43.1% premium. Positive Phase 1 results enable Phase 2 advancement in 2H 2023.
The take-private transaction with MPM BioImpact at a 43.1% premium to the 30-day volume weighted average price is a positive development for Reunion Neuroscience shareholders. Additionally, the positive Phase 1 results and the advancement to Phase 2 in 2H 2023 indicate progress in the company's clinical pipeline, which could positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100